Skip to main content
. 2017 Aug 16;8(39):66491–66503. doi: 10.18632/oncotarget.20281

Table 2. The Assessment of Bias of Included Trials.

Source Sequence
generation
Allocation
concealment
Blinding Incomplete data addressed Selective reporting Other source of
bias
INTERIST,
2008 and 2010
Low risk
(Minimization)
Low risk
(Central allocation)
Unclear risk Low risk Low risk Low risk
TITAN,
2012
Low risk
(Minimization)
Low risk
(Central allocation)
Unclear risk Low risk Low risk Halted prematurely because of slow recruitment
TAILOR,
2013
Low risk
(Minimization)
Low risk
(Central allocation)
Unclear risk Low risk Low risk Low risk
CT/06.05,
2013
Low risk
(Randomized numbers generated by computer)
Low risk
(Central allocation)
Low risk
(Central radiologic review)
Low risk Low risk Low risk
NCT01565538,
2014
Low risk
(Randomized numbers generated by computer)
Unclear risk Unclear risk Low risk Low risk 61% patients in pemetrexed arm crossed over to erlotinib, while 10% patients in erlotinib arm crossed over to pemetrexed.
PROSE,
2014
Low risk
(Minimization)
Low risk risk
(Central allocation)
Unclear risk Low risk Low risk Low risk
DELTA,
2014
Low risk
(Minimization)
Low risk
(Central allocation)
Unclear risk Low risk Low risk Low risk
CTONG 0806,
2014
Low risk
(Minimization)
Low risk risk
(Central allocation)
Low risk
(Independent Review Committee )
Low risk Low risk More nonsmokers in CT arm (57.9% vs 40.7%, p = 0.03)
CheckMate 057,
2015
Low risk
(Minimization)
Low risk
(Central allocation)
Low risk
(Central radiologic review)
Low risk Low risk Low risk
KEYNOTE-010,
2015
Low risk
(Randomized numbers generated by computer)
Low risk
(Central allocation)
Low risk
(Central radiologic review)
Low risk Low risk Low risk
POPLAR,
2016
Low risk
(Randomized numbers generated by bracket)
High risk
(undone)
Low risk
(Central radiologic review)
Low risk Low risk Low risk
OAK,
2016
Low risk
(Minimization)
High risk
(undone)
Low risk
( Central radiologic review)
Low risk Low risk Low risk